Status:
COMPLETED
Sleep and Immune Checkpoint Inhibitors
Lead Sponsor:
Aarhus University Hospital
Collaborating Sponsors:
University of Aarhus
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Sleep disturbances are prevalent in cancer patients and linked to levels of fatigue and depressive symptoms with a major impact on quality of life. A growing body of evidence links sleep disturbances ...
Detailed Description
A total of 240 cancer patients diagnosed with advanced NSCLC, referred to treatment with ICI will be enrolled in this prospective observational study. Patients will be assessed prior to initiation of ...
Eligibility Criteria
Inclusion
- \- Confirmed diagnosis of advanced non-small cell lung cancer
Exclusion
- Insufficient Danish proficiency
- Pre-existing confounding psychiatric illnesses
Key Trial Info
Start Date :
August 5 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2023
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT04070651
Start Date
August 5 2019
End Date
July 1 2023
Last Update
August 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital
Aarhus, Central Jutland, Denmark, 8200